I a recent released study Credit Suisse forecasted that Copaxone Sales would decrease in 2019 to just 400 M from the current 4 B .If that is so that means a yearly reduction in revenues of 360 M roughtly around 9%
Now chose a recently issue revenue decrease by Teva say from 4 q 2012 to 1 q 2013 and you will realize that in spite of a revenue slide of 6.6 % price did not follow suit in fact Teva price increased from 37 to 39.5 .
I think that if Teva keeps pouring new pharmacologic entities into the stream here and there in the next 7 years i think that will do . (its R&D budget will ensure that ) Imao.
* Credit Suisse also foresees an increase in sales of Laquinimod by 1B by the same period.
** Credit Suisse was one of the best stock analyst performers for 2013.